SMT (Sahajanand Medical Technology), a global medical device company focussed on innovative patient care in the cardiovascular segment, headquartered in India today, launched the Hydra TAVR device in Central Europe.
Internationally renowned interventional cardiologists Marek Grygier and Maciej Lesiak deployed Hydra successfully at Poland’s Szpital Kliniczny Przemienienia Pańskiego centre.
Transcatheter Aortic Valve Replacement (TAVR) is an established treatment modality for patients at high risk or unwilling to undergo open-heart valve replacement surgery. The Hydra aortic valve is a self-expandable nitinol based supra-annular aortic system with a mechanism for recapturing the valve during deployment. According to the press release, this technology allows for precise placement of the valve and ensures orthotopic deployment.
Speaking about the successful launch, Marek Kurysz, country head of SMT Poland, said, “This is a significant step forward for SMT in Central Europe. Structural Heart is really a team effort, thanks to Grygier and Lesiak for their trust, Lars Sondergaard, Ole DeBacker for their first class proctoring and the TAVI Research Centre (TRC) in Surat for their world class clinical back end support.”
Adding more to the procedure part, Marek Grygier said, “Hydra aortic valve extends the spectrum of self- expandable valves used in Poland. Based on ESC and Polish Cardiology Society guidelines TAVI operations are performed in patients with heavy stenosis of aortic valve and moderate or increased risk or contraindication to cardiac operation.”
With the Hydra valve, SMT strives to achieve greater patient care length in the structural heart space, just like they have done in the coronary intervention sector globally.
SMT is a global medical device company committed to making advanced medical technologies accessible to everyone worldwide. With a presence in 75 countries, SMT has achieved recognition from the Ministry of Health Sciences and Technologies to contribute to coronary healthcare. SMT also pioneered the introduction of the biodegradable polymer in the cardiovascular segment. SMT will continue the journey to healing hearts by creating a healthcare future promising for everyone.